ZEISS Meditec AG announces commercial availability of ZEISS AT LUCIA toric 721P IOL in Jena, Germany; World’s first bitoric hydrophobic toric IOL

ZEISS announces commercial availability of bitoric hydrophobic monofocal IOL - the ZEISS AT LUCIA toric 721P

Jena, Germany | September 10, 2026 | Carl Zeiss Meditec AG

ZEISS Medical Technology announced today the commercial availability of the ZEISS AT LUCIA toric 721P , the world’s first hydrophobic monofocal toric intraocular lens (IOL) with a bitoric optic combined with a unique asphericity design. The LUCIA ® from ZEISS is the only hydrophobic monofocal IOL family featuring a non-constant asphericity profile design (ZEISS Optic). Built to perform independently of individual eye conditions, the ZEISS LUCIA Family takes into account variations in pupil size, corneal spherical aberration, and natural lens position to offer consistent, reliable outcomes in real world conditions.

The bitoric hydrophobic monofocal IOL ZEISS AT LUCIA toric 721P

Officially launching at the European Society of Cataract and Refractive Surgeons (ESCRS) congress in London from Sept. 11 – 14, the ZEISS AT LUCIA toric 721P IOL is CE marked and now commercially available in select European countries, including Germany, Italy, Spain, Portugal, and France.

“ZEISS once again demonstrates to the market our expertise in optics with a huge leap forward for our IOL offerings. Our broader portfolio will provide surgeons around the world with more options to reach a higher level of patient satisfaction,” says Andreas Völker, Head of the Ophthalmology Strategic Business Unit, ZEISS Medical Technology.

“Providing high reliability and proven lens platform stability, the ZEISS AT LUCIA toric 721P is a game changer, enabling surgeons to elevate their astigmatism management workflow,” says Frank Seitzinger, Head of Business Sector Surgery Anterior Segment, ZEISS Medical Technology.

Celebrating an industry-first innovation at ESCRS

At ESCRS, ZEISS will mark the launch of its new ZEISS AT LUCIA toric 721P IOL with a celebration in the ZEISS booth C.100 in the South Event Hall on Saturday, Sept. 12, from 10:00 – 11:00 AM BST. Attendees will hear from surgeons who participated in early clinical evaluations with the IOL and who will share first-hand insights from their use. Participating surgeons include Prof. Gerd Auffarth from Heidelberg University Hospital (Germany), Dr. Andrea Janeková from Eye Centre Prague (Czech Republic), Dr. Amin Kassem from Värnamo Ögoncenter (Sweden), Dr. Fayyaz Musa from The Eye Doctor Clinic (UK), Dr. Helena Noguera from Miranza COI (Spain), Dr. Felix Rombold from Südblick Augenzentren (Germany), and Prof. Sathish Srinivasan from Ayrshire Eye Clinic (UK), who are also receiving the “ZEISS AT LUCIA toric Pioneer Award” for their pioneering role in adopting the new IOL technology.

To read the surgeons’ clinical perspectives and takeaways following their early implantations of the ZEISS AT LUCIA toric 721P, visit https:

Head of Group Finance & Investor Relations Carl Zeiss Meditec AG

Head of Global Communications Ophthalmology Carl Zeiss Meditec Inc.

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. For more information visit our website at www.zeiss.com

AT LUCIA toric 721P Learn more

ZEISS at ESCRS 2026 Learn more

ZEISS AT LUCIA toric 721P 1 MB Download

ZEISS AT LUCIA toric 721P

ZEISS elevates ophthalmic workflows at ESCRS with new surgical and digital advancements

ZEISS debuts DORC EVA NEXUS for cataract surgery at ESCRS

Get all press releases of the Carl Zeiss Meditec AG here:

Launching at ESCRS in London, the world’s first bitoric hydrophobic monofocal intraocular lens with a non-constant asphericity profile design expands the ZEISS LUCIA Family to treat cataracts while simultaneously correcting astigmatism.

Press & Investor Relations Contact

Not all products, services or offers are approved or offered in every market and approved labelling and instructions may vary from one country to another. For country specific product information, see the appropriate country website.

Frequently Used Products & Solutions MyZEISS Carl Zeiss Meditec AG Investor Relations

About ZEISS About Career Newsroom Compliance ZEISS Workflows

Social Media Facebook Instagram LinkedIn YouTube X

Digital Solutions & Software Development

Select language Global website (English) Internationale Website (Deutsch)

The content of this page was created with help of Generative AI

Legal Contact Publisher Legal Notice Privacy Notice Cookie Notice Cookie Preferences en-INT_36_025_0181I This is a code assigned to all external communications materials, to assist in tracking and monitoring during the internal approval process.

This is a code assigned to all external communications materials, to assist in tracking and monitoring during the internal approval process.